The FDA’s approval of Moderna’s mFLUSIVA marks another major expansion of modified mRNA technology. Approved on August 5 for adults aged 50 and older in the United States, the product is intended for use during the 2026–2027 influenza season and is expected to appear on shelves in the coming weeks.
This deserves immediate attention. Despite all of the harms we witnessed during the COVID-19 rollout, the same dangerous technological platform is now being introduced into routine seasonal influenza inoculation. The United States may be first, but applications are also being considered elsewhere, making this an international issue. Please warn everyone of the dangers and do not take these shots.
If our work resonates with you and you value independent medical investigation, informed consent, and health sovereignty, please consider supporting our ongoing work at DrTrozzi.news.
From COVID-19 to Seasonal Influenza
The COVID-19 injections represented a dramatic departure from traditional vaccine technology. Rather than introducing an antigen directly, the mRNA products deliver tens of trillions of copies of foreign genetic code inside PEGylated lipid nanoparticles, intended to cause the recipient’s own cells to manufacture foreign proteins.
Many of us raised concerns about this technology before the COVID-19 rollout began. Those concerns included the distribution of infinitely penetrating lipid nanoparticles throughout the body, the hyper-persistence of the modified mRNA, the continued production of foreign proteins, and the high risk of serious adverse effects.
The safety signals reported following the COVID-19 rollout only intensified those concerns. Before the COVID-19 injections, there were typically only a few hundred deaths reported each year following vaccination in the United States. This is not accounting for underreporting. After the modified mRNA COVID-19 injections were rolled out, this rose to tens of thousands of reported deaths within months, with higher numbers in those initial months than for all other vaccines, for all other diseases, over the previous 30 years combined. Not to mention, data shows the COVID shots have a negative efficacy; they increase the risk of covid infection. They produced only harm, no benefit.
If we account for the underreporting factors, the COVID-19 rollout has been an ongoing disaster, with upwards of a billion people injured and tens of millions already dead following the injections.
However, instead of stepping back from the technology and acknowledging their concerning risk profile, pharmaceutical companies are expanding its use.
What Is Actually Inside the Final Product?
Independent testing should be a priority as soon as commercial vials become available. Analyses by Kevin McKernan and others of COVID-19 mRNA “vaccine” vials have reported residual plasmid DNA and other manufacturing-related materials that were undisclosed in the ingredient lists. There have also been discoveries of dangerous genetic sequences, rare earth metals, E. coli contamination, and endotoxins. The mFLUSIVA products should therefore be immediately investigated rather than assuming that the finished product contains nothing beyond what appears on the label.
Qualified independent laboratories should examine commercially distributed vials and determine precisely what they contain, including the quantity and integrity of the mRNA, lipid nanoparticle composition, residual DNA, bacterial manufacturing residues, and any other detectable contaminants.
The public must not rely exclusively on manufacturers and regulators for these answers, since they have already proven themselves untrustworthy.
The Existing Flu Shot Raises Its Own Questions
There is another important part of this story: how well do conventional influenza vaccines actually work?
A recent Cleveland Clinic study followed more than 50,000 employees during the 2024–2025 influenza season. In the study population, vaccinated employees experienced a higher cumulative incidence of influenza than unvaccinated employees. The researchers estimated vaccine effectiveness at approximately minus 27%.
This means even in the case of standard vaccination there was a higher, rather than lower, risk of influenza following injection. That finding is particularly relevant when evaluating Moderna’s claims about mFLUSIVA.
Moderna did not establish that mFLUSIVA reduced influenza by 27% compared with receiving no vaccine. Instead, its trial compared the new mRNA product against an existing conventional influenza vaccine and reported roughly 27% greater relative efficacy against laboratory-confirmed influenza. That distinction matters.
Given that the comparator itself is associated with increased infection risk, outperforming it by 27% does not establish that the new product provides substantial protection compared with remaining unvaccinated. 27% better than -27% is essentially negligible.
Safety Matters as Much as Efficacy
Even a genuinely effective medical intervention must still justify its risks.
The adverse reactions that Moderna acknowledged in the mFLUSIVA trial were more frequent and intense than with the conventional flu vaccine comparator. This is an early warning sign of what is likely to come.
For a seasonal respiratory illness, the threshold for demonstrating safety should be exceptionally high. Regulators should demand compelling evidence of meaningful clinical benefit alongside careful long-term safety monitoring. This has not happened.
Demand Evidence Before Expansion
With FDA approval secured, people who have become accustomed to receiving an annual influenza shot may soon be offered an mRNA product instead; likely without their knowledge. The issue also extends far beyond the United States. Moderna has pursued regulatory approval for the product in other jurisdictions, including Canada, Europe, and Australia.
This means urgent action is needed. Once millions of doses have been administered, any harms cannot simply be undone. Not only will injection recipients be at risk, but shedding is also a concern that could potentially affect those around them.
The expansion of mRNA technology from an “emergency” response that was an enormous failure, into routine seasonal vaccination should not happen quietly. mFLUSIVA represents a worrying new stage in the normalization of modified mRNA technology. We must do everything we can to warn everyone we can. Scrutiny needs to happen now, before widespread administration begins.
Contact Your Elected Federal Officials
If you live in the United States, contact your federal representatives today. Alert your Senators and Member of Congress that this is wrong and dangerous. Demand that they intervene to block the rollout of these mRNA flu injections and help warn their constituents about the risks of these genetic products. Find and contact them here: https://www.usa.gov/elected-officials
For everyone else—especially in countries where this product is under review—the time to act is now. Write to your Member of Parliament or equivalent representative. Tell them your public health agency is considering these harmful, misrepresented genetic injections for approval as “vaccines.” Urge them to read this post and the links within it, and to do their part to stop this.
Here are links to contact MPs for the countries most immediately under threat:
Thank you a million times over for this vital message.
They are getting worse! More than 5000 of these useless, dangerous, horrendous shots MAY only keep one person out of the hospital, with completely unknown consequences for the 5000 vax-takers. Other idiots just bought more than $60B of the stock, same as a herd of lemmings!